$3.99
0.25% yesterday
Nasdaq, Jun 13, 10:04 pm CET
ISIN
US45790W1080
Symbol
INZY
Sector
Industry

Inozyme Pharma Inc Stock price

$3.99
+2.90 266.06% 1M
+0.96 31.68% 6M
+1.22 44.04% YTD
-0.86 17.73% 1Y
-13.55 77.25% 5Y
-13.55 77.25% 10Y
-13.55 77.25% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
+0.01 0.25%
ISIN
US45790W1080
Symbol
INZY
Sector
Industry

Key metrics

Market capitalization $257.60m
Enterprise Value $219.11m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 8.09
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-105.48m
Free Cash Flow (TTM) Free Cash Flow $-96.56m
Cash position $84.78m
EPS (TTM) EPS $-1.66
P/E forward negative
Short interest 6.16%
Show more

Is Inozyme Pharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Inozyme Pharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Inozyme Pharma Inc forecast:

1x Buy
13%
7x Hold
88%

Analyst Opinions

8 Analysts have issued a Inozyme Pharma Inc forecast:

Buy
13%
Hold
88%

Financial data from Inozyme Pharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 21 21
7% 7%
-
- Research and Development Expense 85 85
36% 36%
-
-105 -105
30% 30%
-
- Depreciation and Amortization 0.74 0.74
9% 9%
-
EBIT (Operating Income) EBIT -105 -105
29% 29%
-
Net Profit -107 -107
38% 38%
-

In millions USD.

Don't miss a Thing! We will send you all news about Inozyme Pharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Inozyme Pharma Inc Stock News

Neutral
Business Wire
24 days ago
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Inozyme Pharma, Inc. (NasdaqGS: INZY) to BioMarin Pharmaceutical Inc. (NasdaqGS: BMRN). Under the terms of the proposed transaction, shareholders of Inozyme will receive $4.00 in cash for each share of ...
Neutral
PRNewsWire
29 days ago
NEW YORK , May 16, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Charter Communications, Inc. (NASDAQ: CHTR)'s  merger with Cox Communications. If you are a Charter shareholder, click here to learn more about your...
Neutral
Business Wire
29 days ago
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Inozyme Pharma, Inc. (NASDAQ: INZY) to BioMarin Pharmaceutical Inc. for $4.00 per share is fair to Inozyme shareholders. Halper Sadeh encourages Inozyme shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-...
More Inozyme Pharma Inc News

Company Profile

Inozyme Pharma engages in the research and development of pharmaceutical products. It specializes in developing new medicines for the treatment of abnormal mineralization and ABCC6 deficiency. The company was founded by Axel Bolte, Joseph P. Schlessinger and Demetrios T. Braddock in September 2015 and is headquartered in Boston, MA.

Head office United States
CEO Doug Treco
Employees 67
Founded 2015
Website www.inozyme.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today